Written by the Nuvirox Research Team
Key points
- Urolithin A is a gut-microbiome metabolite of pomegranate ellagitannins that triggers mitophagy — the selective recycling of damaged mitochondria. Only some people produce it from food, which is the case for supplementing it.
- In an 88-person randomised trial in middle-aged adults, four months of urolithin A improved muscle strength by around 12% — but missed its primary endpoint of peak power output.
- A separate randomised trial in adults aged 65–90 also failed to improve its primary outcome, the six-minute walk distance. Two well-run trials, two missed primaries, and real secondary signals. Both halves belong in the summary.
Short answer: urolithin A has genuinely better human evidence than most longevity ingredients, and it has still missed the primary endpoint in both of its major randomised trials. The muscle-strength and mitochondrial-biomarker signals are real and were measured properly. The clean, unambiguous functional win has not arrived yet. If you buy it, buy it knowing exactly that.
What is urolithin A and why does the gut matter?
Pomegranates, walnuts and some berries contain ellagitannins. Humans do not absorb those directly. Gut bacteria convert them into urolithins, of which urolithin A is the one of interest. Crucially, not everyone carries the microbial capacity to do this efficiently, which means two people eating identical pomegranate can end up with very different exposure.
That variability is the coherent argument for taking it as a compound rather than eating the fruit. It is also why food-frequency reasoning about pomegranate intake does not map onto the trial data.
What does mitophagy have to do with feeling tired?
Mitochondria accumulate damage. Mitophagy is the quality-control process that tags damaged ones for degradation so the population stays functional. The theory is that declining mitophagy with age leaves a larger fraction of underperforming mitochondria in place, and that muscle — with its enormous energy demand — feels this first.
This is a specific subtype of the broader cellular recycling process; the general version is covered in NAD+ and autophagy. It is worth noting the mechanism is about mitochondrial quality, not quantity, which is a different lever from the one exercise pulls. The energy machinery itself is covered in how your cells actually make energy.
What human studies actually show
The ATLAS trial: strength up, primary endpoint missed. Eighty-eight untrained, overweight middle-aged adults were randomised to urolithin A at two doses or placebo for four months. Muscle strength improved by roughly 12%. Aerobic endurance (peak oxygen consumption) and six-minute walk distance showed changes the authors described as clinically meaningful. Peak power output — the pre-specified primary endpoint — did not improve significantly. Plasma acylcarnitines and C-reactive protein fell, and muscle biopsies showed increased expression of mitophagy-linked proteins.
Study snapshot
| Trial | ATLAS, ClinicalTrials.gov NCT03464500 |
| Design | Randomised, double-blind, placebo-controlled, two doses |
| n / population | 88 untrained, overweight, middle-aged adults |
| Duration | 4 months |
| Primary outcome | Peak power output — not significantly improved |
| Secondary signals | ~12% muscle strength gain; lower plasma acylcarnitines and CRP; increased muscle mitophagy protein expression |
| Funding note | Sponsored by the manufacturer; several authors were employees or board members |
The older-adult trial: primary endpoint missed again. A separate randomised, double-blind, placebo-controlled trial in adults aged 65 to 90, run at a medical centre and cancer research centre in Seattle, assessed six-minute walk distance, hand and leg muscle endurance, and mitochondrial biomarkers at baseline, two months and four months. The six-minute walk distance did not improve significantly versus placebo. The authors noted candidly that improvement in the placebo group likely confounded detection, and that their participants were relatively well-functioning at baseline — mean walk distance around 450 metres — making them less likely to benefit from improved mitochondrial quality control.
Newer work has moved to immune endpoints. A randomised, double-blind, placebo-controlled trial gave 50 healthy middle-aged adults 1,000 mg per day or placebo for four weeks and reported an expansion of naive-like, less terminally exhausted CD8+ T cells (treatment difference 0.50 percentage points; 95% CI 0.16 to 0.83) and increased CD8+ fatty acid oxidation capacity. Interesting mechanistically; four weeks and 50 people is a phase 1 signal, not a health claim.
What urolithin A won’t do
It will not act like a stimulant. Nothing in the trial data suggests an acute perceptible energy effect, and the timescales involved were two to four months.
It also will not substitute for resistance training, which raises muscle strength by considerably more than 12% over four months and does so with a far larger evidence base. If age-related muscle decline is the concern, our piece on NAD+ and muscle loss covers the wider context.
Dose and realistic timeline
Trials have used 500 mg and 1,000 mg daily. The four-month studies used these doses continuously, and biomarker changes in muscle biopsies were measured at the end of that period. The immune trial used 1,000 mg for four weeks.
A realistic expectation, therefore, is a multi-month trial period with strength and endurance as the things to watch, not subjective energy. If you have not noticed anything by four months at a trial-equivalent dose, the honest read is that you are not a responder.
Frequently asked questions
Can I just eat pomegranate instead?
Only if your gut microbiome converts ellagitannins efficiently, and a substantial proportion of people do not. That conversion variability is the single strongest argument for the supplement form over the food.
Why do both trials get described as positive if they missed their primary endpoints?
Because the secondary outcomes moved and the mechanistic biomarkers moved in the expected direction. That is genuinely informative. But a missed primary endpoint means the pre-specified test of the hypothesis failed, and reporting only the secondaries is how supplement marketing goes wrong.
Does urolithin A raise NAD+?
It is not an NAD+ precursor and does not work through that route. Both act on mitochondrial health but by different mechanisms — urolithin A through mitophagy, NAD+ precursors through coenzyme availability.
Is it safe?
Adverse events in the published trials were balanced between groups, and a first-in-human safety study preceded the efficacy work. The durations studied were four months or less, so longer-term safety is uncharacterised.
Who is most likely to benefit?
If the older-adult trial's own explanation is right, people with genuinely low mitochondrial function at baseline. That trial excluded the highest-functioning participants and still ended up with a relatively fit sample, which the authors flagged as a limitation.
From Nuvirox
Why we formulated NAD+ Restore.
Urolithin A and NAD+ precursors target mitochondrial health from different angles. We formulated NAD+ Restore around the coenzyme side, with the precursor that has the deeper human trial record.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek — to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Urolithin A is one of the more credible ingredients in this category, and the reason is that its manufacturer funded proper randomised trials with biopsies, pre-specified endpoints and published null results. That is more integrity than the field usually shows. The fair reading is that mitophagy activation in human muscle is real, the strength signal is real, and neither trial hit the outcome it set out to hit. Give it four months at a trial-equivalent dose if you want to test it, watch strength rather than mood, and keep training — because the intervention with the largest effect on muscle in that timeframe is still resistance exercise.
References
- Singh A, D’Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633. PMID: 35584623. PMCID: PMC9133463. ClinicalTrials.gov: NCT03464500.
- Liu S, D’Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Network Open. 2022;5(1):e2144279. DOI: 10.1001/jamanetworkopen.2021.44279.
- Denk D, Singh A, Kasler HG, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. PMID: 41174221.
- Dunn J, Grider MH. Physiology, adenosine triphosphate. StatPearls. NCBI Bookshelf ID: NBK553175.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.